Precigen, Inc. ( (PGEN) ) has released its Q2 earnings. Here is a breakdown of the information Precigen, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Precigen, Inc. is a biopharmaceutical company focused on advancing gene and cell therapies to address significant unmet medical needs, primarily in the fields of immuno-oncology, autoimmune disorders, and infectious diseases. The company recently released its earnings report for the second quarter of 2025, highlighting ongoing financial challenges and strategic shifts.
In the latest earnings report, Precigen reported a net loss of $26.6 million for the second quarter of 2025, a significant improvement from the $58.8 million loss in the same period last year. Total revenues for the quarter were $856,000, up from $717,000 in the previous year, driven by increased service revenues. However, the company continues to face substantial operating expenses, including research and development costs and impairment charges.
Key financial metrics from the report indicate that Precigen’s cash and cash equivalents have decreased to $13.8 million from $29.5 million at the end of 2024. The company also reported a significant increase in warrant liabilities, which rose to $78.6 million from $50.5 million. Despite these challenges, Precigen is focused on the potential commercialization of its leading product candidate, PRGN-2012, which is under priority review by the FDA with a target action date in late August 2025.
Looking ahead, Precigen’s management remains cautiously optimistic about the future, emphasizing the importance of regulatory approval for PRGN-2012 and the potential revenue it could generate. The company is also exploring additional financing options to support its operations and strategic initiatives. However, there is still uncertainty surrounding the company’s ability to continue as a going concern, given its current financial position and ongoing cash flow challenges.